CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20 enrolled
Drug / intervention
ethosomal preparation of anthralin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03348462
NCT03348462Phase 4Completed

Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis

Assiut University·interventional·Posted Nov 21, 2017·Updated Mar 10, 2020

In Brief

A Phase 4 clinical trial evaluating ethosomal preparation of anthralin and liposomal preparation of anthralin for Psoriasis Vulgaris. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Psoriasis is a common immune mediated inflammatory skin disease characterized by red heavily scaled plaques. Anthralin (1,8-dihydroxy-9-anthrone) which was introduced over 80 years ago has shown excellent efficacy in the management of psoriasis.Although anthralin is remarkably effective in the management of psoriasis, its side effects are equally disturbing. Its use is messy as it stains the skin, clothing, and any furniture that it may come in contact with. Further, anthralin has irritating, burning, brown discoloration and necrotizing effect on the normal and the diseased skin. This troublesome profile has discouraged wide-spread use of the drug. Ethosomes are attractive vesicular carriers mainly composed of phospholipids, ethanol and water. The intriguing features of ethosomes are due to their high ethanol content which facilitate their penetration through stratum corneum and target deep skin layers. This is advantageous over conventional liposomes which have limited penetration through the skin and remain confined in the upper layer of the stratum corneum. Compared to liposomes, ethosomes had greater retention of methotrexate into the skin for a longer period of time, suggesting better therapeutic outcome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesEgypt
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedNov 21, 2017
Enrollment StartNov 30, 2017
Primary CompletionDec 30, 2019
Study CompletionJan 15, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.6 years ago

Interventions

ethosomal preparation of anthralindrug

once daily with short contact topical application

liposomal preparation of anthralindrug

once daily with short contact topical application